中央検査室市場：サービスタイプ別、治療領域別、フェーズ別、エンドユーザー産業別-2025-2030年の世界予測

中央検査室市場は、2024年に37億2,000万米ドルと評価され、2025年にはCAGR 6.25%で39億6,000万米ドルに成長し、2030年には53億6,000万米ドルに達すると予測されています。

ダイナミックな中央検査室の世界では、進化は日常業務の一部であるだけでなく、戦略的進歩の礎石でもあります。本エグゼクティブサマリーでは、セントラルラボの現状を詳細に分析し、最近の動向と今後の方向性を明らかにします。急速な技術の進歩、顧客の要求の進化、精密医療への関心の高まりにより、検査室は日常的な検査施設から高度なイノベーション拠点へとその役割を再定義しつつあります。

この変革の根底にあるのは、品質、効率、臨床的妥当性への新たなフォーカスです。検査室は現在、パフォーマンスとアウトカムを最適化するために、データ分析、高度なロボット工学、新しい診断手法を統合しています。本稿では、変革的なシフトを論じ、セグメンテーションの洞察を掘り下げ、戦略的な地域と企業の視点を提供することで、業界の包括的な検証の舞台を整えます。この調査を通じて、業界のリーダー、意思決定者、利害関係者は、この分野がどこに向かっているのか、そして将来の成功のためにこれらの機会をどのように活用すべきかについて、微妙な理解を得ることができます。

本レポートは、業務効率と長期的な戦略投資の両方を取り上げ、イノベーションを促進しながら最新の市場動向との整合性を確保しています。読者は、中央検査部門が、従来はサポート機能と見なされていたが、ヘルスケア提供の極めて重要な要素に成熟していることを知ると思われます。この変革は、厳密な科学的探究、データ主導のプロセス、そして患者の転帰改善へのコミットメントによって推進されています。さらに読み進めると、確かなデータと専門家の洞察に裏打ちされた、この分野を再構築しつつある重要なテーマが見えてくる。

中央検査室市場の変革

中央研究所を取り巻く環境は、いくつかの要因によって激変しています。テクノロジーの導入は拡大し続け、ラボは単なる検査施設ではなく、イノベーションのためのセンターとして位置付け直されています。最も影響力のある動向のひとつは、オペレーションを合理化し、ヒューマンエラーの可能性を減らす高度な自動化システムの導入です。これらのシステムは精度を高めるだけでなく、迅速な納期を可能にし、検査結果をより迅速に臨床医に提供します。

さらに、デジタルトランスフォーメーションは、臨床データの処理と分析に大きなパラダイムシフトをもたらしました。データ管理機能の強化により、検査室は機械学習や人工知能を活用できるようになり、複雑なデータセットに対する深い洞察が得られるようになりました。これらのツールがより洗練されるにつれ、予測分析とリアルタイムの意思決定が規範となる文化が醸成されています。検査施設はこれらの技術を活用して、患者の転帰の動向を予測し、資源配分を最適化し、さらには個々の患者のニーズに合わせて検査プロトコルを調整するようになっています。

イノベーションはまた、品質保証とコンプライアンスをますます重視するようになった規制環境の進化によっても推進されています。中央検査室にとって、厳格なガイドラインを満たすだけでなく、エビデンスに基づいた信頼性の高い結果を提供することが不可欠となっています。このような流れの中で、品質管理手順が見直され、最先端の機器によって強化され、検査室が科学的革新の最前線にあり続けることを保証しています。

この変革期は、戦略的協力関係によっても特徴づけられます。研究機関、バイオテクノロジー企業、診断ラボ間のパートナーシップは、画期的な発見を推進し、臨床転帰を改善する上で不可欠なものとなりつつあります。このような協力関係は、専門知識とリソースの共有を可能にし、継続的な改善と学習のエコシステムを育みます。革新的研究と臨床応用の統合を促進し、現代ヘルスケアの複雑な課題に対応するために不可欠な相乗効果を生み出します。

検査施設はこうした変化に適応する一方で、競争が激化する市場の需要に対応するため、運営戦略の見直しも行っています。デジタルトランスフォーメーションの波は、科学的厳密性の向上や戦略的パートナーシップと相まって、中央検査室の状況を一変させつつあります。この進化は、精密医療と個別化医療が理論的な概念から日常的な実践へと急速に移行しているヘルスケアシステム内の広範な動向を反映しています。

市場セグメンテーションの洞察が市場理解を深める

セントラルラボ分野の市場力学を理解する上で欠かせないのが、深いセグメンテーション分析です。サービスタイプ、治療領域、運営フェーズ、エンドユーザーカテゴリーなど、さまざまな切り口で市場を調査することで、利害関係者はパターンを特定し、戦略を最適化することができます。例えば、サービスタイプに注目すると、市場は解剖学的病理学／組織学、バイオマーカーサービス、遺伝子サービス、微生物学サービス、特殊化学サービス、検体管理・保管などの専門領域にわたって綿密に調査されています。このきめ細かなアプローチにより、これらのセグメント間で異なる独自の能力と技術的ニーズを特定し、分類することができます。

治療分野を掘り下げることで、臨床検査室における微妙な需要がさらに浮き彫りになります。同市場は、自己免疫疾患、心血管疾患、感染症、神経学、腫瘍学を含む広範な領域に対して調査されています。特に、自己免疫疾患分野では、自己抗体プロファイリングとサイトカイン分析に焦点を当て、専門的な診断技術がどこで卓越した牽引力を獲得しているかについての明確な見解を提供しています。これらの区分は、現在の市場ニーズを示すだけでなく、研究開発への投資が大きな利益をもたらす可能性のある分野を示しています。

さらに、臨床試験のステージは、しばしば第I相、第II相、第III相に分類されるが、これも重要なセグメンテーションの軸となります。各段階には、独自の運用、規制、技術的要件があります。中央検査室市場をこれらのフェーズにわたって評価することにより、検査室はワークフローとコンプライアンスプロセスを調整し、初期の探索的試験から後期の確認研究まで臨床試験の体系的な進行を確実にサポートすることができます。

セグメンテーション分析はエンドユーザー産業にも及んでいます。市場は、学術・調査機関、バイオテクノロジー企業、病理・診断研究所、製薬会社など、複数の主要産業にわたって調査されています。これらの多様な視点を市場全体の分析に統合することで、ラボは自社の製品を特定の顧客ニーズや市場の需要により合致させることができます。このような多角的な視点は、サービスのカスタマイズだけでなく、サプライチェーン・ロジスティクスや規制遵守の全体的な最適化も促進します。

このような競合考察は、競合のポジショニングを強化し、経済的価値を最大化するターゲット戦略の開発に不可欠です。サービスの種類、治療の焦点、臨床段階、エンドユーザーの属性などの相互関係を理解することで、利害関係者はデータに基づいた意思決定を行うことができます。このようなきめ細かな分析は、市場の成功の中核をなすものであり、ニッチな専門化に利用可能な機会と、広範な戦略的改善が大きな利益をもたらす可能性のある領域の両方を浮き彫りにするものです。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 新たな薬剤処方を必要とする慢性疾患の蔓延
    • 世界中で中央検査室業務のアウトソーシングが増加傾向
    • 臨床試験への研究開発投資が世界的に増加
  • 抑制要因
    • 中央検査室における物流とサンプルの取り扱いに関する懸念
  • 機会
    • ポイントオブケア検査の導入増加と個別化医療への傾向の高まり
    • 患者中心のヘルスケアモデルの継続的な発展
  • 課題
    • 中央研究所に関連する複雑な規制枠組みへの対応
• 市場セグメンテーション分析
  • サービスタイプ：特定の管理のために管理された条件下で生物学的サンプルを長期保管するための中央研究所を優先
  • フェーズ：臨床試験プロセス全体の実行における中央研究所の重要な役割
  • 最終用途：製薬会社のデータの完全性と運用の卓越性を確保しながら、シームレスな臨床試験を促進する必要がある
  • 治療領域：腫瘍学および感染症の治療領域における包括的な診断および予後検査
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 中央検査室市場：サービスタイプ別

• 解剖病理学/組織学
• バイオマーカーサービス
• 遺伝子サービス
• 微生物学サービス
• 特殊化学サービス
• 標本管理と保管

第7章 中央検査室市場治療領域別

• 自己免疫疾患
  • 自己抗体プロファイリング
  • サイトカイン分析
• 心血管疾患
• 感染症
• 神経学
• 腫瘍学

第8章 中央検査室市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII

第9章 中央検査室市場エンドユーザー産業別

• 学術調査機関
• バイオテクノロジー企業
• 病理学および診断ラボ
• 製薬会社

第10章 南北アメリカの中央検査室市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の中央検査室市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの中央検査室市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• Almac Group
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories International, Inc
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• GBA Group
• ICON plc
• IQVIA Inc.
• Laboratory Corporation of America Holdings
• Lambda Therapeutic Research Ltd.
• Medicover AB
• Medpace, Inc.
• Novotech Health Holdings
• Pace Analytical Services, LLC
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• REPROCELL Inc.
• SGS S.A.
• Siemens Healthineers AG
• SMS Pharmaceuticals Ltd.
• Syngene International Limited
• Thermo Fisher Scientific Inc.
• Waters Corporation

LIST OF FIGURES

• FIGURE 1. CENTRAL LAB MARKET MULTI-CURRENCY
• FIGURE 2. CENTRAL LAB MARKET MULTI-LANGUAGE
• FIGURE 3. CENTRAL LAB MARKET RESEARCH PROCESS
• FIGURE 4. CENTRAL LAB MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CENTRAL LAB MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CENTRAL LAB MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES CENTRAL LAB MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES CENTRAL LAB MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. CENTRAL LAB MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. CENTRAL LAB MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CENTRAL LAB MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CENTRAL LAB MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CENTRAL LAB MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CENTRAL LAB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL LAB MARKET DYNAMICS
• TABLE 7. GLOBAL CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CENTRAL LAB MARKET SIZE, BY ANATOMIC PATHOLOGY/HISTOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CENTRAL LAB MARKET SIZE, BY BIOMARKER SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CENTRAL LAB MARKET SIZE, BY GENETIC SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CENTRAL LAB MARKET SIZE, BY MICROBIOLOGY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CENTRAL LAB MARKET SIZE, BY SPECIAL CHEMISTRY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CENTRAL LAB MARKET SIZE, BY SPECIMEN MANAGEMENT & STORAGE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CENTRAL LAB MARKET SIZE, BY AUTOANTIBODY PROFILING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CENTRAL LAB MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CENTRAL LAB MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CENTRAL LAB MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CENTRAL LAB MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CENTRAL LAB MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CENTRAL LAB MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CENTRAL LAB MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CENTRAL LAB MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CENTRAL LAB MARKET SIZE, BY PATHOLOGY & DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CENTRAL LAB MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CENTRAL LAB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CENTRAL LAB MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CENTRAL LAB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 75. CHINA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CHINA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 77. CHINA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 78. CHINA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. CHINA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 80. INDIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 82. INDIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. INDIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 84. INDIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA CENTRAL LAB MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 166. ITALY CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 167. ITALY CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 168. ITALY CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. ITALY CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 170. ITALY CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 186. POLAND CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 187. POLAND CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 188. POLAND CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. POLAND CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 190. POLAND CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 191. QATAR CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 192. QATAR CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 193. QATAR CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 194. QATAR CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 195. QATAR CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM CENTRAL LAB MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM CENTRAL LAB MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM CENTRAL LAB MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM CENTRAL LAB MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM CENTRAL LAB MARKET SIZE, BY END-USER INDUSTRIES, 2018-2030 (USD MILLION)
• TABLE 241. CENTRAL LAB MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 242. CENTRAL LAB MARKET, FPNV POSITIONING MATRIX, 2024

The Central Lab Market was valued at USD 3.72 billion in 2024 and is projected to grow to USD 3.96 billion in 2025, with a CAGR of 6.25%, reaching USD 5.36 billion by 2030.

In the dynamic world of central laboratories, evolution is not only a part of daily operations but also a cornerstone of strategic progress. This executive summary provides an in-depth look at the current state of the central lab landscape, highlighting recent trends and future directions. With rapid technological advancements, evolving customer demands, and a heightened focus on precision medicine, laboratories are redefining their roles from routine testing facilities to sophisticated innovation hubs.

Underpinning this transformation is a renewed focus on quality, efficiency, and clinical relevance. Laboratories are now integrating data analytics, advanced robotics, and novel diagnostic methodologies to optimize performance and outcomes. This paper sets the stage for a comprehensive examination of the industry by discussing transformative shifts, delving into segmentation insights, and offering strategic regional and corporate perspectives. Through this exploration, industry leaders, decision-makers, and stakeholders can gain a nuanced understanding of where the field is headed and how to leverage these opportunities for future success.

This report addresses both operational efficiency and long-term strategic investments, ensuring alignment with the latest market trends while fostering innovation. Readers will find that the central lab sector, though traditionally regarded as a support function, has matured into a pivotal element of healthcare delivery. This transformation is fueled by rigorous scientific inquiry, data-driven processes, and a commitment to improved patient outcomes. As you read further, you will explore key themes that are reshaping the field, backed by robust data and expert insights.

Transformative Shifts in the Central Lab Landscape

The central lab environment is experiencing a radical transformation driven by several interlocking factors. Technology adoption continues to grow, repositioning laboratories as centers for innovation rather than mere testing facilities. One of the most influential trends is the incorporation of advanced automation systems that streamline operations and reduce the possibility of human error. These systems not only enhance accuracy but also allow for quicker turnaround times, making lab results more rapidly available to clinicians.

Furthermore, digital transformation has brought about a significant paradigm shift in the processing and analysis of clinical data. Enhanced data management capabilities are enabling labs to leverage machine learning and artificial intelligence, providing deeper insights into complex datasets. As these tools become more sophisticated, they foster a culture where predictive analytics and real-time decision-making are the norms. Labs are harnessing these technologies to predict trends in patient outcomes, optimize resource allocation, and even tailor testing protocols to individual patient needs.

Innovation is also driven by an evolving regulatory environment that increasingly emphasizes quality assurance and compliance. It has become imperative for central labs to not only meet strict guidelines but to also deliver evidence-based, reliable results. In this vein, quality control procedures are being overhauled and enhanced with state-of-the-art instrumentation, ensuring that laboratories remain at the forefront of scientific innovation.

This period of transformation is also marked by strategic collaborations. Partnerships between research institutions, biotech companies, and diagnostic labs are becoming essential in driving breakthrough discoveries and improving clinical outcomes. Such collaborations enable the sharing of expertise and resources, fostering an ecosystem of continuous improvement and learning. They facilitate the integration of innovative research with clinical application, creating synergies that are vital for responding to the complex challenges of modern healthcare.

As laboratories adapt to these changes, they are also recalibrating their operational strategies to meet the demands of an increasingly competitive market. The wave of digital transformation, coupled with heightened scientific rigor and strategic partnerships, is revolutionizing the central lab landscape. This evolution reflects broader trends within the healthcare system, where precision and personalized medicine are rapidly moving from theoretical concepts to everyday practice.

Key Segmentation Insights That Drive Market Understanding

An integral part of understanding the market dynamics in the central lab sector lies in deep segmentation analysis. By examining the market through various lenses, such as service type, therapeutic area, phase of operation, and end-user categories, stakeholders can identify patterns and optimize their strategies. For instance, when looking at service type, the market is meticulously studied across specialized domains such as Anatomic Pathology/Histology, Biomarker Services, Genetic Services, Microbiology Services, Special Chemistry Services, and Specimen Management & Storage. This granular approach allows for the identification and categorization of unique capabilities and technological needs that vary between these segments.

Delving into therapeutic areas further highlights the nuanced demand within clinical labs. The market is surveyed against a broad spectrum including Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, and Oncology. Particularly, the autoimmune disease segment is dissected further with a focus on Autoantibody Profiling and Cytokine Analysis, offering a clear view on where specialized diagnostic techniques are gaining exceptional traction. These distinctions not only inform the current market needs but also indicate areas where investment in research and development could yield substantial returns.

Furthermore, the stage of clinical trials, often categorized into Phase I, Phase II, and Phase III, serves as another critical segmentation anchor. Each phase has unique operational, regulatory, and technical requirements. By assessing the central lab market across these phases, laboratories can adjust their workflows and compliance processes, ensuring that they support the systematic progression of clinical studies from early exploratory trials to later-stage confirmatory research.

The segmentation analysis extends to end-user industries as well. The market is studied across several key industries including Academic & Research Institutions, Biotechnology Companies, Pathology & Diagnostic Labs, and Pharmaceutical Companies. By integrating these diverse perspectives into the overall market analysis, laboratories can better align their offerings with specific customer needs and market demands. This multi-dimensional view facilitates not only the tailoring of services but also the optimization of supply chain logistics and regulatory compliance across the board.

These segmentation insights are essential for developing targeted strategies that enhance competitive positioning and maximize economic value. By understanding the interplay between service type, therapeutic focus, clinical phase, and end-user demographics, stakeholders are equipped to make data-driven decisions. This granular analysis is at the heart of market success, highlighting both the opportunities available for niche specialization as well as areas where broad-based strategic improvements can yield significant benefits.

Based on Service Type, market is studied across Anatomic Pathology/Histology, Biomarker Services, Genetic Services, Microbiology Services, Special Chemistry Services, and Specimen Management & Storage.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, and Oncology. The Autoimmune Diseases is further studied across Autoantibody Profiling and Cytokine Analysis.

Based on Phase, market is studied across Phase I, Phase II, and Phase III.

Based on End-User Industries, market is studied across Academic & Research Institutions, Biotechnology Companies, Pathology & Diagnostic Labs, and Pharmaceutical Companies.

Regional Insights: Impact, Trends, and Market Dynamics

A comprehensive understanding of the central lab landscape requires a detailed look at regional markets. Variations across global regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific not only reflect cultural and economic differences but also reveal divergent regulatory environments and investment priorities. Each region offers a unique set of challenges and opportunities that are critical in shaping regional strategies.

In the Americas, laboratories are at the forefront of adopting advanced technologies and innovative testing methodologies. The region boasts significant investment in research, a robust infrastructure, and dynamic partnerships across public and private sectors. This has resulted in accelerated research activities and high levels of operational efficiency. Moreover, the emphasis on integrated healthcare services in this region encourages the adoption of combined diagnostic and research models, which further bolsters the capabilities of central labs.

Across Europe, Middle East & Africa, regulatory frameworks tend to be characterized by strict compliance requirements coupled with a strong push for quality and reliable diagnostics. The emphasis in these regions lies in maintaining rigorous testing standards while also accommodating the growing need for personalized medicine. The strategic adaptations required for regulation, along with the continuous influx of capital in the sector, create both pressure and opportunity for laboratories to innovate. The region is actively involved in public-private partnerships, which help drive forward the research and development agenda, ensuring that labs remain competitive on both a local and global scale.

The Asia-Pacific region, meanwhile, is witnessing a sharp rise in investments in biotechnology and healthcare infrastructure. As many countries in this region strive to bridge the gap between emerging market dynamics and advanced healthcare solutions, laboratories are increasingly prioritizing scalability, cost-efficiency, and technological innovation. Here, the integration of digital tools and automation has become pivotal in addressing the unique challenges posed by high-volume testing and diverse patient demographics. The rapid growth in this region is encouraging laboratories to explore new business models and regional collaborations that enhance both productivity and service quality.

Analyzing these regional trends provides critical insights that help laboratories tailor their strategies to specific market conditions. Understanding regional dynamics enables labs to anticipate regulatory changes, respond to local healthcare demands, and make informed investment decisions. This strategic approach is essential for maintaining a competitive edge in an increasingly complex and interconnected global marketplace.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company Insights: Leaders Driving Innovation and Market Trends

The central lab sector thrives on the contributions of leading companies that are dedicated to technological innovation, rigorous standardization, and strategic market positioning. Influential organizations are driving transformation by investing heavily in R&D and forging strategic alliances to enhance their service portfolio. Market leaders such as Abbott Laboratories, Agilent Technologies, Inc., Almac Group, Bio-Rad Laboratories, Inc., and Charles River Laboratories International, Inc have set benchmarks in quality and performance.

Other major players, including Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, GBA Group, and ICON plc, are recognized for their pioneering approaches and commitment to advancing diagnostic capabilities. Firms like IQVIA Inc., Laboratory Corporation of America Holdings, and Lambda Therapeutic Research Ltd. further exemplify excellence in driving comprehensive integration of laboratory technology with clinical research, enabling smoother transitions across various phases of clinical trials.

Industry stalwarts such as Medicover AB, Medpace, Inc., and Novotech Health Holdings have built reputations for their state-of-the-art diagnostic solutions and robust service networks that cover broad geographical and operational spectrums. Pace Analytical Services, LLC, QIAGEN N.V., and Quest Diagnostics Incorporated consistently push the envelope with innovative testing protocols and unparalleled precision. The contributions of REPROCELL Inc., SGS S.A., and Siemens Healthineers AG highlight the integration of automation and quality control measures, ensuring that the central lab sector remains adaptive and resilient under changing market conditions.

Not to be overlooked are key players like SMS Pharmaceuticals Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., and Waters Corporation, whose commitment to both customer centricity and scientific excellence is evident in every facet of their operations. Their continued innovation and strategic market positioning underscore the importance of embracing technological change, operational excellence, and a proactive approach to meeting ever-evolving market requirements.

The dynamic competitive environment is fueled by robust investment in research, operational efficiencies, and strategic collaborations. These companies are not only reactive to market trends; they are shaping them by leading initiatives that set quality benchmarks, drive operational standards, and champion scientific discovery. Their strategic activities and continuous enhancements in technological capabilities are pivotal in ensuring that the central lab industry remains a vital component of the healthcare ecosystem.

The report delves into recent significant developments in the Central Lab Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Almac Group, Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, GBA Group, ICON plc, IQVIA Inc., Laboratory Corporation of America Holdings, Lambda Therapeutic Research Ltd., Medicover AB, Medpace, Inc., Novotech Health Holdings, Pace Analytical Services, LLC, QIAGEN N.V., Quest Diagnostics Incorporated, REPROCELL Inc., SGS S.A., Siemens Healthineers AG, SMS Pharmaceuticals Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., and Waters Corporation. Actionable Recommendations for Future Industry Leadership

To remain competitive in a rapidly evolving market, industry leaders must adopt a proactive approach that combines technological innovation, operational excellence, and strategic partnerships. First, investing in automation and digital transformation is imperative. As laboratories integrate advanced robotics and data analytics, the resulting improvements in operational efficiency and data accuracy will provide a significant competitive advantage. Leaders should prioritize investments in technologies that streamline workflows, reduce manual errors, and enable scalable operations.

Secondly, fostering strategic partnerships and collaborations is essential. By aligning with research institutions, technology providers, and regulatory bodies, labs can accelerate innovation cycles and share key insights that drive overall improvement in service quality and process efficiency. Collaborative efforts ensure that the latest scientific advances are seamlessly integrated into operational protocols, thus enhancing diagnostic capabilities and patient outcomes.

It is also recommended that industry leaders increase their focus on personalized medicine and precision diagnostics. Tailoring testing protocols to cater to specific therapeutic areas will lead to more targeted and effective treatments. Leaders should consider adopting segmented strategies that address specialized needs across therapeutic areas including Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Neurology, and Oncology. This targeted approach allows for a more refined allocation of resources and enhances the effectiveness of diagnostic interventions.

Moreover, attention should be given to regulatory alignment and quality control measures. As the industry navigates an evolving regulatory landscape, maintaining compliance with rigorous standards is non-negotiable. Leaders must thus embed robust quality assurance processes within every layer of their operations. Developing training programs and quality metrics can help ensure that employees remain abreast of the latest industry standards and regulatory requirements.

Finally, continuous market intelligence and agile strategy formulation are indispensable. Regularly updated market insights, coupled with real-time data analytics, allow for swifter reaction to market changes. This dynamic strategy formulation should be backed by thorough competitive analysis, enabling companies to forecast market trends and adjust their business models accordingly. By staying rooted in data-driven decision-making, industry leaders can ensure sustainability and long-term growth in an increasingly complex marketplace.

Conclusion: Strategic Reflection on Central Lab Evolution

In summary, the central lab landscape is characterized by ongoing transformation driven by technological advancements, complex segmentation, and a diverse range of regional and corporate influences. This executive summary has navigated through the essential dimensions of the industry-from a robust introduction setting the stage for change, to a detailed exploration of transformative shifts in technology and collaborations. The segmentation insights reveal that market dynamics are intricately linked to varied service types, therapeutic focuses, clinical phases, and end-user needs, while regional analysis highlights the nuanced variations across global markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific.

Furthermore, the market is shaped by the influential actions of leading companies that are continuously pushing the boundaries of innovation and excellence. Their commitment to research, strategic partnerships, and quality control reinforces the sector's ability to adapt and thrive in times of change. These insights are integral for decision-makers aiming to navigate the complexities of today's competitive environment.

As laboratories reflect on their journey and future prospects, it becomes clear that the path forward will be defined by the integration of advanced technologies, strategic collaboration, and a relentless focus on quality. The evolution of the central lab is not a destination but a continuous process of reinvention, with every new innovation offering fresh opportunities and challenging traditional norms. The lessons drawn from this comprehensive analysis underscore the importance of agility, detailed strategic planning, and a commitment to excellence in shaping the future of central laboratory operations.

The industry stands at a critical juncture where informed decision-making and proactive investment in new technologies will pave the way for sustained growth and innovation. Viewing the current transformation through a strategic lens empowers leaders to harness this momentum and achieve groundbreaking success in the realm of diagnostics and laboratory management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases necessitating novel drug formulations
    • 5.1.1.2. Growing trend toward outsourcing of central lab work globally
    • 5.1.1.3. Rising research and development investments in clinical trial globally
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with logistics and sample handling in central lab
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased adoption of point-of-care testing and growing trend toward personalized medicine
    • 5.1.3.2. Ongoing developments in patient-centered healthcare models
  • 5.1.4. Challenges
    • 5.1.4.1. Addressing complex regulatory frameworks associated with central labs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Service Type: Preference for central labs for long-term storage of biological samples under controlled conditions for specific management
  • 5.2.2. Phase: Integral role of the central labs for the execution of the entire clinical trial process
  • 5.2.3. End-use: Need to facilitate seamless clinical trials, ensuring data integrity and operational excellence for pharmaceutical companies
  • 5.2.4. Therapeutic Area: Comprehensive diagnostic and prognostic testing for oncology and infectious diseases therapeutic areas
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Central Lab Market, by Service Type

• 6.1. Introduction
• 6.2. Anatomic Pathology/Histology
• 6.3. Biomarker Services
• 6.4. Genetic Services
• 6.5. Microbiology Services
• 6.6. Special Chemistry Services
• 6.7. Specimen Management & Storage

7. Central Lab Market, by Therapeutic Area

• 7.1. Introduction
• 7.2. Autoimmune Diseases
  • 7.2.1. Autoantibody Profiling
  • 7.2.2. Cytokine Analysis
• 7.3. Cardiovascular Diseases
• 7.4. Infectious Diseases
• 7.5. Neurology
• 7.6. Oncology

8. Central Lab Market, by Phase

• 8.1. Introduction
• 8.2. Phase I
• 8.3. Phase II
• 8.4. Phase III

9. Central Lab Market, by End-User Industries

• 9.1. Introduction
• 9.2. Academic & Research Institutions
• 9.3. Biotechnology Companies
• 9.4. Pathology & Diagnostic Labs
• 9.5. Pharmaceutical Companies

10. Americas Central Lab Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Lab Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Lab Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Pace Life Sciences achieves FDA approval for Oakdale central lab, boosting CDMO service expansion
  • 13.3.2. QPS Holdings expands cell therapy and laboratory services to meet rising demand in clinical trials
  • 13.3.3. Labcorp launches new tools to speed up clinical trials
  • 13.3.4. Medpace Central Labs Expand Singapore Facility
  • 13.3.5. Vial Announces Collaborative Alliance with MLM Medical Labs for offering Central Laboratory Solutions
  • 13.3.6. Cleveland Clinic and LabConnect announce Strategic Alliance for Improved Patient Care
  • 13.3.7. Versiti Acquires Indiana-based Quantigen for Accelerating Pace of Innovation for Preclinical Research Services
  • 13.3.8. Labor Dr. Wisplinghoff and Labconnect Announce Strategic Alliance - Expanding Global Central Laboratory Services to Accelerate the Development of Medicines
  • 13.3.9. IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
  • 13.3.10. Cerba Research Offers a Customized, Innovative Approach to its Partners in the Laboratory Services
  • 13.3.11. Medpace Central Labs Expand Histology & Anatomic Pathology Services
  • 13.3.12. Thermo Fisher to invest USD 59 Million for Clinical Research Lab Expansion in the U.S.
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. Almac Group
• 4. Bio-Rad Laboratories, Inc.
• 5. Charles River Laboratories International, Inc
• 6. Eurofins Scientific SE
• 7. F. Hoffmann-La Roche Ltd
• 8. GBA Group
• 9. ICON plc
• 10. IQVIA Inc.
• 11. Laboratory Corporation of America Holdings
• 12. Lambda Therapeutic Research Ltd.
• 13. Medicover AB
• 14. Medpace, Inc.
• 15. Novotech Health Holdings
• 16. Pace Analytical Services, LLC
• 17. QIAGEN N.V.
• 18. Quest Diagnostics Incorporated
• 19. REPROCELL Inc.
• 20. SGS S.A.
• 21. Siemens Healthineers AG
• 22. SMS Pharmaceuticals Ltd.
• 23. Syngene International Limited
• 24. Thermo Fisher Scientific Inc.
• 25. Waters Corporation